The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma.
G. P. Kim
No relevant relationships to disclose
N. R. Foster
No relevant relationships to disclose
M. Salim
No relevant relationships to disclose
P. J. Flynn
No relevant relationships to disclose
D. F. Moore
No relevant relationships to disclose
R. Zon
No relevant relationships to disclose
R. B. Mowat
No relevant relationships to disclose
M. Wiesenfeld
No relevant relationships to disclose
A. E. McCullough
No relevant relationships to disclose
S. R. Alberts
No relevant relationships to disclose